High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer research hub

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

This study is testing a new targeted cancer drug called azenosertib. It is for women with advanced ovarian, fallopian tube, or peritoneal cancer that has returned after standard platinum chemotherapy. Researchers want to see if azenosertib works better than standard chemotherapy options at keeping the cancer under control.